[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nausea\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nausea":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,61,102,133,156,181,204,225,250,280,306,332,359,388,409],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100573018","phase-4-broadening-antiemetics-research-by-comparing-the-effectiveness-of-fosaprepitant-and-metoclopramide-100573018",false,"NCT06740812","Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide","Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide: A Randomized Control Trial","BARF RCT","Inclusion Criteria:\n\n* Adults at least 18 years old\n* Present to ED for treatment of Nausea and\u002For vomiting as defined by the International Classification of Diseases (ICD-10) or identified by treating clinician\n\nExclusion Criteria:\n\n* Pregnancy, desiring pregnancy, or lactating\n* Antiemetic use or intravenous fluids prior to presenting to ED for evaluation and management\n* Bradycardia (\\\u003C 60 bpm heart rate)\n* Prolonged QTc (greater than 490ms)\n* Not conversant in English or Spanish\n* Altered mental status\n* Dementia\n* Lack of phone for follow-up communication","ALL","18 Years",{"count":20,"type":21},212,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The study team proposes a double-blind, comparative effectiveness, randomized controlled trial (RCT) to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic metoclopramide. Fosaprepitant and its active metabolite aprepitant are a relatively new class of antiemetic that exclusively acts in the central nervous system by blocking neurokinin (NK-1) which is a key signaling molecule in the centrally mediated aspects of the vomiting reflex. Currently, fosaprepitant and aprepitant both have only two United Stated Food and Drug Administration (USFDA) approved indications for nausea and vomiting: chemotherapy-induced and postoperative. Neurokinin inhibitors are highly effective and generally well-tolerated. Therefore, this class of medication may be a more appropriate medication for the millions of patients with nausea and vomiting that seek care in emergency departments (EDs). Intravenous fosaprepitant is converted to the active metabolite aprepitant on the order of minutes and is significantly cheaper to procure at this time.",[27,28,29],"Nausea and Vomiting","Nausea","Vomiting",[31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47],"Signs and Symptoms, Digestive","Antiemetics","Autonomic Agents","Peripheral Nervous System Agents","Physiological Effects of Drugs","Gastrointestinal Agents","Antipruritics","Dermatologic Agents","Neurotransmitter Agents","Molecular Mechanisms of Pharmacological Action","Neurokinin-1 Receptor Antagonists","Fosaprepitant","Aprepitant","Dopamine Receptor Antagonist","Randomized Control Trial","Metoclopramide","Adults","NOT_YET_RECRUITING","2026-06-25",{"date":51,"type":52},"2026-06-29","ACTUAL",{"date":54,"type":21},"2026-12",{"date":56,"type":21},"2027-09",{"name":58,"class":59},"Montefiore Medical Center","OTHER",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":73,"conditions":74,"keywords":85,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":60},"100557838","marginal-ulcer-healing-with-low-thermal-argon-plasma-endoscopic-treatment-100557838","NCT06543316","Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment","Accelerated Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment","AMULET","Inclusion Criteria:\n\n* Subjects aged 18 years and above, inclusive of both males and females.\n* Patients with a history of Roux-en-Y gastric bypass (RYGB) presenting symptoms indicative of marginal ulcers (MUs) such as abdominal pain, nausea, vomiting, gastrointestinal bleeding, or dysphagia.\n* Subjects must be scheduled for an EGD for the evaluation of these symptoms.\n* Marginal ulcers confirmed during the initial EGD.\n* Willingness to adhere to the SOC treatment, which includes PPIs.\n* Subjects able to tolerate repeated endoscopic procedures.\n* Capacity for providing informed consent and understanding of study requirements.\n* Willingness and ability to attend required follow-up assessments at 4 weeks (+\u002F- 1 week) and 8 weeks (+\u002F- 2 weeks).\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Unwillingness to undergo repeated endoscopies.\n* Inability or unwillingness to comply with the SOC.\n* Current use of systemic antibiotics.\n* Any condition deemed by the investigator to compromise the safety of undergoing an endoscopic procedure.\n* Pregnancy, lactation, or absence of reliable contraception in women of childbearing potential.\n* Current enrollment in another investigational trial with potential to interfere with this study's endpoint analyses.",{"count":70,"type":21},100,[72],"NA","The objective of the study is to investigate the treatment of marginal ulcers with Low Thermal plasma in an endoscopic setting. By a treatment of the ulcerated areas with argon plasma with low power settings (\\~ 1 W) we hypothesize that the size of the ulcers will shrink, and the healing is accelerated compared to standard of care alone. Patients will benefit from this minimally invasive approach compared to a much more invasive surgical approach that comes with higher risks and hospital stay length time. From a societal and scientific perspective, this study aims to extend the well-documented clinical benefits of plasma technology - from external wound healing to internal ulcer treatment - within an endoscopic framework. The success of this study could pave the way for broader applications of LTP in the treatment of other endoscopically accessible conditions such as peptic ulcers, duodenal ulcers and esophageal ulcers. This advancement has the potential not only to improve patient outcomes through less invasive methods, but also to position LTP as a cornerstone in the future of gastroenterological wound management strategies.",[75,76,77,78,79,80,81,28,29,82,83,84],"Roux-en-y Anastomosis Site","Marginal Ulcer","Marginal Ulcer (Peptic) or Erosion","Ulcer","Ulcer, Gastric","Ulcer Gastrointestinal","Abdominal Pain","GastroIntestinal Bleeding","Dysphagia","Ulcer Gastrojejunal",[86,87,88,89,90,91,92],"Argon Plasma Coagulation","APC","Low-Thermal Argon Plasma Endoscopic Treatment","Endoscopy","RYGB","Roux-en-Y Gastric Bypass","Ulcer Healing","RECRUITING","2026-06-23",{"date":49,"type":52},{"date":97,"type":52},"2025-03-04",{"date":99,"type":21},"2028-06",{"name":101,"class":59},"Christopher C. Thompson, MD, MSc",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":132},"100606000","phase-2-a-study-to-evaluate-ly3537021-for-the-treatment-of-nausea-and-vomiting-caused-by-chemotherapy-in-adults-with-cancer-100606000","NCT07169851","A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease","Inclusion Criteria:\n\n* Chemotherapy-naive participants, planned to receive AC or cisplatin-based chemotherapy greater than or equal to (≥)70 milligrams per square meter (mg\u002Fm²), on Day 1 of each cycle, with no multiple administrations during the CINV observation period, from Day 2 to Day 5 of each cycle.\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n\nExclusion Criteria:\n\n* Have symptomatic or untreated central nervous system (CNS) metastases.\n* Have an established diagnosis of uncontrolled diabetes mellitus.\n* Have a history of, or current evidence of, a clinically significant cardiac condition or QT\u002FQTcF-related conditions.\n* Have another etiology for nausea and vomiting, or receives medications with know or potential antiemetic activity\n* Signs, symptoms or history of thyroid tumors\n* Receives treatment with a gastric inhibitory polypetide (GIP) or glucagon-like peptide-1 (GLP-1) receptor agonist within 4 weeks prior to chemotherapy.\n* Have participated in a clinical study involving study intervention within 30 days of Cycle 1 Day 1 (C1D1). If the previous study intervention has a long half-life, within 3 months or 5 halflives, whichever is longer, of C1D1.\n* Are pregnant, breastfeeding, or intend to become pregnant during the study or within 30 days of the last dose of study intervention.",{"count":110,"type":21},204,[112],"PHASE2","The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months.",[28,29,115,116],"Drug-Related Side Effects and Adverse Reactions","Neoplasms",[118,119,120,121,122],"Chemotherapy-Induced Nausea and Vomiting (CINV)","Anthracycline and cyclophosphamide (AC)","Glucose-dependent Insulinotropic Peptide (GIP)","Incretins","Cisplatin","2026-06-19",{"date":94,"type":52},{"date":126,"type":52},"2025-11-28",{"date":128,"type":21},"2027-02",{"name":130,"class":131},"Eli Lilly and Company","INDUSTRY",67,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":60},"100545446","phase-2-antiemetic-fosaprepitant-to-remedy-nausea-and-vomiting-100545446","NCT06382012","Antiemetic Fosaprepitant To Remedy Nausea and Vomiting","AFTR NV RCT","Inclusion Criteria:\n\n* Adults at least 18 years old\n* Present to an emergency department (ED) for nausea and\u002For vomiting as defined by the International Classification of Diseases (ICD-10), or identified by treating clinician\n* Following the approval of a protocol amendment, study patients who have received an antiemetic and remain persistently nauseated after 2 hours will be eligible to participate in the study\n\nExclusion Criteria:\n\n* Pregnancy, desiring pregnancy, or lactating\n* Antiemetic medication use less than 2 hours prior to screening\n* Bradycardia (heart rate less than 60 bpm heart rate)\n* Prolonged QTc (\\>480ms)\n* Not conversant in English or Spanish\n* Altered mental status\n* Dementia\n* Lack of phone for follow-up communication",{"count":141,"type":21},200,[112,143],"PHASE3","The study team proposes a randomized, double-blind, RCT to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic ondansetron. Fosaprepitant and its active metabolite aprepitant are a relatively new class of antiemetic that exclusively acts in the central nervous system by blocking neurokinin (NK-1) which is a key signaling molecule in the centrally mediated aspects of the vomiting reflex. Currently, fosaprepitant and aprepitant both have only two United Stated Food and Drug Administration (USFDA) approved indications for nausea and vomiting: chemotherapy-induced and postoperative. Neurokinin inhibitors are highly effective and generally well-tolerated. Therefore, this class of medication may be a more appropriate medication for the millions of patients with nausea and vomiting that seek care in EDs. Intravenous fosaprepitant is converted to the active metabolite aprepitant on the order of minutes and is significantly cheaper to procure at this time. The outcome for the efficacy analysis will be no need for additional medication to treat nausea and vomiting within 2 hours of investigational medication administration. The primary outcome for the tolerability analysis will be the development of any new symptom within 2 hours of medication administration.",[27,28,29],[42,29,45,147,47],"Ondansetron","2026-05-14",{"date":150,"type":52},"2026-05-18",{"date":152,"type":52},"2024-11-13",{"date":154,"type":21},"2027-03",{"name":58,"class":59},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100551810","chronic-nausea-and-vomiting-in-patients-with-normal-gastric-emptying-using-the-enterra-therapy-system-navigate-100551810","NCT06464926","Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)","A Prospective Randomized Controlled Trial of Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System","NAVIGATE","Inclusion Criteria:\n\n* Willing and able to complete the informed consent process\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Aged ≥18 years at time of informed consent\n* Chronic, drug-refractory nausea that: a) has been present for more than 6 months, and b) has been active within the last 3 months prior to consent\n* Patient is able to complete ANMS GCSI-DD surveys on a compatible smart device with: a) a minimum of four (4) ANMS GCSI-DD entries per week for two consecutive weeks, and b) an average ANMS GCSI-DD score for nausea severity of ≥2.5 during the same two-week period\n* Refractory or intolerant to two or more of the following antiemetic drug classes: antihistamines, phenothiazines, serotonin type 3 receptor antagonists, dopamine type 2 receptor antagonists, anticholinergics, neurokinin receptor antagonists\n* Medically stable, in the opinion of the investigator, during the month prior to consent, with no planned modifications to medical therapy during the course of the study\n* Normal gastric emptying as assessed by a qualifying gastric emptying test performed within 2 years of consent if no prior pyloric transection therapy, or within 2 years of consent and after the most recent pyloric transection therapy\n* Normal upper endoscopy within 1 year prior to consent (e.g., absence of obstructions, ulcers, or cancers in the esophagus, stomach, or duodenum) performed within 1 year of consent if no prior pyloric transection therapy, or within 1 year of consent and after the most recent pyloric transection therapy\n\nExclusion Criteria:\n\n* Cognitive impairment or other characteristic that would limit a patient's ability to complete study requirements\n* Pyloric transection therapy completed within 1 year of consent\n* Documented gastrointestinal (GI) obstruction or pseudo-obstruction\n* History of primary swallowing disorders\n* History of primary psychogenic vomiting\n* History of primary eating disorder\n* History of cyclic vomiting syndrome\n* History of rumination syndrome\n* History of scleroderma\n* History of amyloidosis\n* History of cannabis hyperemesis syndrome\n* Active H. pylori infection\n* Evidence of bezoar during most recent endoscopy\n* Previous gastric surgery of any type other than a pyloric transection therapy (i.e., pyloroplasty, pyloromyotomy, POP, or G-POEM)\n* Uncontrolled thyroid disorder, in the opinion of the investigator\n* History of seizures disorders\n* Hemoglobin A1c \\>8.0%\n* Peritoneal dialysis or unstable hemodialysis\n* Parenteral or enteral nutritional support\n* Active pancreatitis\n* History of organ transplant, gross malabsorptive syndromes, celiac disease, or inflammatory bowel disease\n* Other GI tract diseases and disorders that the investigator believes may have caused the patient's drug-refractory nausea and\u002For vomiting\n* Malignancy (with the exception of basal cell carcinoma of the skin) currently present, initially diagnosed or recurring within 5 years of consent\n* Opioid use\n* Current cannabis\u002Fcannabinoid use that exceeds: 3 days of usage per week, or 2 occurrences during each day of use, or 3 grams of total usage per week\n* Heavy alcohol use, defined as: for men, consuming five or more drinks on any day or 15 or more per week; for women, consuming four or more drinks on any day or 8 or more per week\n* Injection of Botox into the pyloric sphincter within 6 months of consent\n* Active major levels of anxiety\u002Fdepression, as determined by the investigator\n* History of other clinically significant disease, or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the patient or impact the validity of the study results\n* Life expectancy \\\u003C1 year\n* Pregnant or breastfeeding at the time of consent or intend to become pregnant during the study\n* Any underlying disease leading to follow-up by MRI outside of current MR conditional indications\n* Glucagon-like peptide 1 (GLP-1) agonist drug use within 6 months of consent\n* Participation in other investigational clinical studies\n* Existing or prior gastric electrical stimulator implantation",{"count":165,"type":21},148,[72],"The purpose of this research study is to determine if the Enterra® Therapy System can decrease nausea and vomiting symptoms and improve the quality of life for patients with chronic nausea, with or without vomiting, that have normal gastric emptying.",[28,29],[170,28,29,171],"Chronic","Gastric Electrical Stimulation","2026-05-11",{"date":148,"type":52},{"date":175,"type":52},"2025-06-23",{"date":177,"type":21},"2030-06",{"name":179,"class":131},"Enterra Medical, Inc.",22,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":60},"100608957","phase-3-olanzapine-plus-metoclopramide-for-the-prevention-of-opioid-induced-nausea-and-vomiting-100608957","NCT07208305","Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting","Inclusion criteria\n\n1. Patients with malignant tumors diagnosed by pathology or histology;\n2. Patients diagnosed with locally advanced or advanced stages by imaging;\n3. Age ≥ 18 years old;\n4. The eastern cooperative oncology group (ECOG) performance status of 0-3;\n5. The expected survival period shall be no less than 4 weeks;\n6. Moderate or severe cancer pain with a Numerical Rating Scale (NRS) score of ≥ 4 points;\n7. Be able to take oral medication;\n8. Initial treatment with potent opioid painkillers (such as morphine, oxycodone, fentanyl, etc.);\n9. No systemic chemotherapy or radiotherapy was received within one month prior to selection, and no drugs that may induce nausea and vomiting were used.\n10. There were no gastrointestinal discomforts such as nausea or vomiting at the time of selection, and no intestinal obstruction.\n11. Possess normal comprehension and communication skills, be capable of completing research evaluations and following research procedures.\n\nExclusion criteria\n\n1. Diabetic patients with a clear diagnosis and poorly controlled blood sugar levels;\n2. There are symptoms of nausea or vomiting;\n3. Symptomatic intracranial diseases, such as brain metastases or leptomeningeal metastasis;\n4. Received chemotherapy drug treatment within one week before the trial medication or during the trial period;\n5. Receive radiotherapy for the head, abdomen or pelvic cavity within one week before the trial or during the trial;\n6. New drugs with emetic or antiemetic effects have been used within 48 hours before the start of the trial;\n7. Patients with severe electrolyte imbalance, abnormal kidney or liver function;\n8. Patients with gastrointestinal bleeding;\n9. Pregnant or lactating women;\n10. Patients diagnosed with breast cancer;\n11. Those whose electrocardiogram examination indicates heart disease or prolonged QTc interval;\n12. There is a history of allergy or contraindications to olanzapine or metoclopramide.",{"count":188,"type":21},222,[143],"The goal of this clinical trial is to evaluate the efficacy and safety of olanzapine plus metoclopramide in preventing opioid-induced nausea and vomiting (OINV) in adult patients with advanced cancer who are initiating strong opioid therapy. The main questions it aims to answer are: (1) Does the combination of olanzapine and metoclopramide reduce the incidence of OINV? (2)What adverse events do participants experience when taking the combination of olanzapine and metoclopramide? Researchers will compare the olanzapine-metoclopramide combination to a no prophylactic treatment control group to determine whether the combination is effective in preventing OINV.\n\nParticipants will: Take olanzapine (2.5 mg\u002Fday ) and metoclopramide (10 mg three times daily) or receive no prophylaxis for 7 days; Through follow-up, nausea, vomiting, the time of the first attack of nausea and vomiting, the duration of nausea and vomiting, the use of strong opioids and adverse events were evaluated and recorded, as well as the pain score (using NRS) and quality of life (EQ-5D-5L) of the patients were evaluated at baseline and on day 7.",[28,29],[193,46,194,28,29],"Olanzapine","Opioid","2026-04-23",{"date":197,"type":52},"2026-04-27",{"date":199,"type":52},"2026-02-03",{"date":201,"type":21},"2027-12-30",{"name":203,"class":59},"Affiliated Hospital of Qinghai University",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":210,"minAge":18,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":60},"100622070","alternate-nostril-breathing-anb-for-1st-trimester-nausea-and-vomiting-100622070","NCT07378839","Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting","Inclusion Criteria:\n\n* Pregnant individuals aged 18 years or older\n* Viable pregnancy with a gestational age between 6 0\u002F7 - 12 6\u002F7 weeks of gestation, confirmed by last menstrual period or ultrasound\n* Diagnosed with mild to moderate NVP (PUQE-24 score between 4-12)\n* Ability to understand and read English\n\nExclusion Criteria:\n\n* Severe nausea and vomiting, defined as a PUQE score \\>12, or diagnosis of hyperemesis gravidarum requiring hospitalization or intravenous fluid therapy\n* Pre-existing, active or acute respiratory conditions (e.g., asthma, COPD)\n* History of severe anxiety disorders affecting breathing patterns\n* Known deviated nasal septum\n* Nausea and vomiting that pre-dates the pregnancy or is suspected to be due to a etiology other than pregnancy","FEMALE",{"count":70,"type":21},[72],"This is a prospective, two-arm, non-blinded randomized controlled study designed to evaluate the effects of a one-week alternate nostril breathing (ANB) intervention on nausea and vomiting severity in pregnant individuals during their first trimester.",[215,28],"Pregnancy Emesis","2026-03-16",{"date":218,"type":52},"2026-03-19",{"date":220,"type":52},"2026-02-10",{"date":222,"type":21},"2027-03-31",{"name":224,"class":59},"University of Minnesota",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":232,"sex":17,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":60},"100471389","phase-2-inhaled-isopropyl-alcohol-for-treatment-of-nausea-100471389","NCT05418244","Inhaled Isopropyl Alcohol for Treatment of Nausea","Inhaled Isopropyl Alcohol for the Treatment of Nausea in a Pediatric Emergency Department: A Open Label, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with a chief complaint of nausea or vomiting\n* Ages 7-178 years, both sexes\n* Weight ≥ 15 kg\n* Baxter Animated Retching Faces (BARF) nausea severity score ≥ 4\u002F10\n\nExclusion Criteria:\n\n* 1\\. Require IV access\n* Inability to breathe in\u002Fout through the nose\n* Anosmia (self- or parental report)\n* Allergy to isopropyl alcohol or ondansetron\n* Current or history of alcohol abuse\n* Inability to communicate feeling nauseous\n* Inability to follow directions regarding taking deep breaths through the nose\n* Known prolonged QT interval\n* Pregnancy\n* Received antiemetics within the last 8 hours\n* Currently taking apomorphine",true,"7 Years","17 Years",{"count":236,"type":21},84,[112,143],"To determine the efficacy of inhaled isopropyl alcohol in treating nausea\u002Fvomiting among pediatric patients compared with the conventional ondansetron, or placebo treatment in a tertiary care pediatric emergency department.",[29,28,240],"Children, Only","2025-10-03",{"date":243,"type":52},"2025-10-08",{"date":245,"type":52},"2022-04-20",{"date":247,"type":21},"2026-06-30",{"name":249,"class":59},"State University of New York at Buffalo",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":17,"minAge":257,"maxAge":18,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":259,"briefSummary":260,"conditions":261,"keywords":265,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":279},"100294904","phase-2-rct-of-olanzapine-for-control-of-civ-in-children-receiving-highly-emetogenic-chemotherapy-100294904","NCT03118986","RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy","Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-induced Vomiting in Children Receiving Highly Emetogenic Chemotherapy","Planned receipt of HEC or cyclophosphamide ≥ 1 g\u002Fm2\u002Fday (≥ 33 mg\u002Fkg\u002Fday) for cancer treatment or autologous or allogeneic HSCT conditioning.81,82 Examples of HEC are: busulfan IV (myeloablative dosing), carboplatin ≥175mg\u002Fm²\u002Fdose, cisplatin ≥12mg\u002Fm²\u002Fdose, cytarabine ≥3g\u002Fm²\u002Fday, melphalan \\>140mg\u002Fm², methotrexate ≥12g\u002Fm²\u002Fdose and thiotepa ≥300mg\u002Fm²\u002Fdose.\n\nPlan for inpatient admission from administration of first study drug dose until 24 hours following administration of last study drug dose.\n\nBody weight of at least 12.5 kg\n\n2.5 to \\\u003C 18 years of age. Note that the minimum age requirement corresponds to an approximate body weight of 12.5 kg.\n\nSamples for all laboratory tests will be obtained within one week prior to administration of the first chemotherapy dose of the study chemotherapy block or the first HSCT conditioning dose:\n\n* Plasma creatinine within 1.5 times the upper limit of normal for age.\n* Amylase within age-appropriate limits\n* Plasma conjugated bilirubin within ≤ 3x upper limit of normal for age unless attributable to Gilbert's Syndrome\n* ALT ≤ 5x upper limit of normal for age\n\nBaseline ECG within the month prior to study drug administration without known clinically significant abnormalities including pathologic prolongation of QTc\n\nA plan for scheduled, round-the-clock receipt of ondansetron, granisetron or palonosetron for antiemetic prophylaxis during administration of chemotherapy or HSCT conditioning.\n\nNegative pregnancy test if female of childbearing potential\n\nPatients of childbearing potential must consent to use adequate contraception (males and females) or agree to practice abstinence\n\nParent or child able to speak a language in which the (modified Pediatric Adverse Event Rating Scale (PAERS) is available.\n\nOptional: Child participants in the optional assessment of nausea severity must be 4 to 18 years of age. Child and a parent\u002Fguardian must be English, Spanish or French-speaking. The Pediatric Nausea Assessment Tool58 (PeNAT) is validated in English-speaking children 4 to 18 years old with an English-speaking parent\u002Fguardian and has been translated into Spanish and French. The MAT is available in English, Spanish and French.","30 Months",{"count":141,"type":21},[112],"Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy",[262,28,263,264],"Vomiting in Infants and\u002For Children","Hematopoietic System--Cancer","Oncology",[266,267,268,269,270,271],"olanzapine","vomiting","children","adolescents","bone marrow transplant","supportive care",{"date":243,"type":52},{"date":274,"type":52},"2017-08-10",{"date":276,"type":21},"2026-04",{"name":278,"class":59},"The Hospital for Sick Children",10,{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":289,"briefSummary":290,"conditions":291,"keywords":294,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":4},"100606710","the-effect-of-a-protective-oral-care-protocol-using-peppermint-oil-mouthwash-100606710","NCT07179094","The Effect of a Protective Oral Care Protocol Using Peppermint Oil Mouthwash","The Effect of a Protective Oral Care Protocol Using Peppermint Oil Mouthwash on Chemotherapy-Induced Nausea, Vomiting, and Loss of Appetite in Patients With Hematologic Malignancies","Inclusion Criteria:\n\n* Age 18 years or older\n* Clinical diagnosis of hematologic malignancy\n* History of at least one chemotherapy cycle\n* Scheduled to receive chemotherapy with high or moderate emetogenic risk agents\n* No oral mucositis before chemotherapy\n* No metastasis\n* Literate (able to read and write)\n* Volunteer to participate in the study\n\nExclusion Criteria:\n\n* Use of herbal remedies for nausea, vomiting, or anorexia\n* Concurrent radiotherapy with chemotherapy\n* Non-adherence to standard antiemetic therapy according to the chemotherapy preparation regimen and protocol (e.g., use of antiemetics other than granisetron or metoclopramide)\n* Known allergy to peppermint oil\n* Psychiatric disorders\n* Communication impairments (hearing or speech difficulties)\n* Altered level of consciousness\n* Endotracheal intubation\n* Requirement for oral care solutions other than the clinic's routine procedures (saline or sodium bicarbonate)\n* Chronic gastrointestinal diseases (gastritis, gastric\u002Fpeptic ulcer, ulcerative colitis, Crohn's disease, gastroesophageal reflux, irritable bowel syndrome, cirrhosis, or pancreatitis)\n* Migraine\n* Brain metastases\n* Hepatic or renal insufficiency\n* Administration of low-emetogenic chemotherapy\n* Mucositis (Oral Assessment Guide score: 15-24 points)",{"count":288,"type":21},72,[72],"Hematologic malignancies are the fifth most common type of cancer in the world. Patients with hematologic malignancies receive long-term and exhausting treatments such as chemotherapy, radiotherapy, hematopoietic stem cell transplantation and supportive therapies. Chemotherapy-induced nausea and vomiting has a significant impact on the daily lives of patients and causes physiological effects such as anorexia, malnutrition, weight loss, dehydration and electrolyte imbalance. It also has a negative impact on activities of daily living and psychological status, and may lead to poor adherence to chemotherapy regimens, refusal of chemotherapy or discontinuation of treatment. Oral mucosa is one of the areas most affected by the cytotoxic damage of chemotherapy. Disruption of the oral mucosa causes nausea, vomiting and feeding problems. Patients resort to non-drug approaches to manage these problems. It is important that these non-pharmacologic approaches are supported and controlled by reliable and evidence-based studies in order to prevent adverse effects on patient outcomes. In the literature, it has been determined that peppermint oil has antiemetic, antiseptic, anti-inflammatory, analgesic, antiseptic, antioxidant, antiviral, antifungal and spasmolytic effects, protects the integrity of the oral mucosa and has positive effects on nausea-vomiting and anorexia.\n\nIn this context, the aim of the study was to investigate the effect of a preventive oral care protocol with peppermint oil mouthwash on chemotherapy-induced nausea, vomiting and appetite in patients with hematologic malignancy.\n\nResearch Hypotheses H01: The protective oral care protocol applied with peppermint oil in patients with hematological malignancies has no effect on the development of chemotherapy-induced nausea and vomiting.\n\nH02: The protective oral care protocol applied with peppermint oil in patients with hematological malignancies has no effect on the severity of chemotherapy-induced nausea and vomiting.\n\nH03: The protective oral care protocol applied with peppermint oil in patients with hematological malignancies has no effect on the development of chemotherapy-induced anorexia.\n\nH04: The protective oral care protocol applied with peppermint oil in patients with hematological malignancies has no effect on the severity of chemotherapy-induced anorexia.\n\nMethods: The type of study is a single-blind randomized controlled experimental study. The research will be conducted between September 10, 2025, and April 10, 2026, with patients admitted to the hematology clinic of a university hospital for chemotherapy treatment. The study will be conducted with a total of 72 people who will be randomly assigned to the intervention (n=36) and control groups (n=36) by stratified and block randomization method. Patients who are 18 years of age or older, have hematologic malignancy, with a history of at least one chemotherapy cycle, and scheduled to receive chemotherapy with high or moderate emetogenic risk agents, do not have oral mucositis before chemotherapy, do not have metastasis, are literate and volunteer to participate in the study will be included in the study. Research data will be collected using the \"Patient Introduction Form\", \"Rhodes Nausea-Vomiting and Retching Index\", \"Oral Assessment Guide\", \"Appetite Assessment Chart \\[(Visual Analog Scale (VAS)\\]\", \"Peppermint Oil Protective Oral Care Protocol\", \"Food Intake Record Form\", \"Allergic Reaction Monitoring Form\" and \"Patient Monitoring Form and Antiemetic Record Chart\". In addition to the routine protective oral care (saline solution mouthwash and\u002For sodium bicarbonate mouthwash) in the clinic, \"Peppermint Oil Protective Oral Care Protocol\" will be applied to the intervention group for 6 days from the start of chemotherapy treatment. Patients will receive mouthwash prepared with 1 ml of peppermint oil and 50 ml of prepared drinking water 3 times a day. Patients in the intervention group will be monitored for 6 days by evaluating oral assessment, development of oral mucositis, appetite follow-up and compliance with mouthwash. The development of allergy due to the use of peppermint oil in each mouthwash application will be evaluated. The control group will not receive any oral care intervention by the researcher and will receive routine preventive oral care in the clinic. In the evaluation of the data, descriptive statistics, Chi-square \u002F Fisher's Exact test will be used for the relationship between categorical variables, Mann Whitney U test, Wilcoxon test, Kruskal-Wallis H test will be used for the relationship between continuous variables in groups that do not show normal distribution; one-way analysis of variance \u002F repeated measures analysis of variance, t test for dependent and independent groups will be used in groups with normal distribution. Correlation analysis and regression analysis will be used to examine the relationship between variables.",[292,28,29,293],"Hematologic Neoplasms","Anorexia",[292,28,29,293,295,296],"Prevention Mouthrinse","peppermint oil","2025-09-15",{"date":299,"type":52},"2025-09-17",{"date":301,"type":21},"2025-09-10",{"date":303,"type":21},"2026-06-10",{"name":305,"class":59},"Şule Güzle",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":232,"sex":17,"minAge":18,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":330,"locationsCount":60},"100589478","periorbital-massage-for-nausea-and-vomiting-after-laparoscopic-surgery-100589478","NCT06954935","Periorbital Massage for Nausea and Vomiting After Laparoscopic Surgery","Effectiveness of Periorbital Massage in the Management of Nausea and Vomiting After Laparoscopic Cholecystectomy","Inclusion Criteria:\n\nThose who have laparoscopic cholecystectomy surgery under general anesthesia,\n\n* Those between the ages of 18-70,\n* Those who do not have a psychiatric disease,\n* Those who understand what they read and volunteer patients,\n* Those who do not have a hearing or speech problem,\n\nExclusion Criteria:\n\n* Patients undergoing emergency surgery,\n\n  * Patients with psychiatric disorders\n  * Patients who have taken another antiemetic drug within 24 hours before surgery","70 Years",{"count":315,"type":21},2,[72],"Laparoscopic cholecystectomy is one of the commonly used surgical treatment methods for gallbladder diseases. However, many patients experience significant nausea and vomiting after laparoscopic cholecystectomy. It is observed that approximately 20% to 30% of patients experience postoperative nausea and vomiting as the most common complaint after laparoscopic cholecystectomy. This study aims to investigate the effectiveness of periorbital massage in postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy.",[28,29,319],"Laparoscopic Cholecystectomy",[321,322,323],"nausea","voming","periorbital massage","2025-04-30",{"date":326,"type":52},"2025-05-02",{"date":328,"type":52},"2025-04-23",{"date":301,"type":21},{"name":331,"class":59},"Atlas University",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":232,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":342,"briefSummary":343,"conditions":344,"keywords":348,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":4},"100574183","icough-bundle-and-postoperative-pain-and-nausea-after-laparoscopic-cholecystectomy-100574183","NCT06755970","ICOUGH Bundle and Postoperative Pain and Nausea After Laparoscopic Cholecystectomy","The Effect of the ICOUGH Bundle Applied Under Nurse Leadership on Pain and Nausea After Laparoscopic Cholecystectomy: a Randomized Controlled Study","ICOUGHBundle","Inclusion Criteria:\n\n* Those who agree to participate in the study and volunteer\n* Aged 18 and above\n* Undergoing laparoscopic cholecystectomy surgery under general anesthesia\n* Those without physical or mental disabilities, limitations, or conditions that would prevent them from performing respiratory exercises (such as the use of medications affecting respiration, conditions requiring oxygen therapy, etc.)\n* Those whose cognitive level is suitable for the application of scales\n* Patients without communication problems will be included in the study\n\nExclusion Criteria:\n\n* Those whose hemodynamic values are not stable after the surgical intervention\n* Those who develop any complications such as severe bleeding, nausea, vomiting, etc., after surgery\n* Patients with acute or chronic lung diseases\n* Patients who voluntarily wish to withdraw from the study will not be included in the study",{"count":341,"type":21},80,[72],"This study will use a randomized controlled experimental research design. The population of the study will consist of all adult patients who undergo laparoscopic cholecystectomy at the General Surgery Clinic of Atatürk University Research Hospital between December 2024 and September 2025. The data will be collected using a Descriptive Information Form and the Visual Analogue Scale. The research has received institutional approval and ethics committee approval. The study will be conducted with collaboration from healthcare professionals in the clinic after they have been informed. Patients who meet the inclusion criteria will be invited to participate in the study after being approached one day before surgery. Oral and written consent will be obtained from those who volunteer and agree to participate. The data will be analyzed using SPSS for Windows 22 software.",[319,345,346,347],"Pain","ICOUGH","NAUSEA",[345,349,28],"Laparoscopic cholecystectomy","2025-02-12",{"date":352,"type":52},"2025-02-14",{"date":354,"type":21},"2025-03-01",{"date":356,"type":21},"2025-12-01",{"name":358,"class":59},"Ataturk University",{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":232,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":22,"phases":367,"briefSummary":368,"conditions":369,"keywords":373,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":4},"100562494","effects-of-different-aroma-therapies-on-nursing-students-100562494","NCT06603896","Effects of Different Aroma-therapies on Nursing Students.","Effects of Single and Combined Aromatherapy on Nursing Student Anxiety, Test Anxiety, Nausea or Queasiness, Exam Grades, GPA, and Perceived Stress","Inclusion Criteria:\n\n* nursing students\n* 18 years of age or older\n* Male or Female\n* all ethnicities will be included\n\nExclusion Criteria:\n\n* cognitive impairments interring with reading, comprehending, following directions\n* unstable psychiatric impairments\n* chronic depression\n* severe anxiety disorders\n* asthma,\n* fragrance allergy\n* rhinitis\n* upper respiratory tract infection\n* lower respiratory tract infection\n* smell\u002Fodor impairments\n* allergies to plant-based essential oils\n* pregnancy",{"count":70,"type":21},[72],"The aim of this study is to investigate the use of lavender and citrus inhalation aromatherapy on anxiety, test anxiety and sleep quality in Pace University sophomore, junior and senior nursing majors. Anxiety, particularly test anxiety, is a ubiquitous problem among nursing students. Test anxiety is a type of state anxiety experienced as concern or fear before, during, or following a test or performance assessment. While some anxiety may enhance the performance of a student, test anxiety often negatively effects performance. Although test anxiety can be incapacitating to any student, in nursing students it can not only have a negative impact on learning, it is a major cause for under-achievement and prevents some students from reaching their academic potential since they are enrolled in a high-stakes program.\n\nTreatment for test anxiety includes counseling, desensitization therapy, relaxation therapies, and aromatherapy. Aromatherapy with its focus on the therapeutic use of plant oils has the ability to decrease anxiety in humans through the use of natural oils particularly Lavandula angustifolia (lavender) without the potential for adverse reactions or side effects of conventional anxiolytic drugs.\n\nResearch on the efficacy of aromatherapy on test anxiety in college and nursing students shows mixed results. A variety of designs and essential oil scents, either mixed or single, were used with subjects, e.g., lavender, rosemary, peppermint, lemon and the vehicles used to administer the oils, e.g., room diffused inhalation, non-absorbent cloth infused lavender for the aromatherapy vary.\n\nHowever, studies using lavender essential oil to reduce anxiety in college students, nursing students, and patients, demonstrated that lavender overall acted as an effective anxiolytic in reducing the stress of test taking, especially with lower levels of anxiety. Thus lavender essential oil could benefit nursing students in reducing test anxiety, and has great potential in benefiting all students in test and anxiety reduction, provided the person is not allergic to the oil. There is support for the notion that aromatherapy is a safe intervention, in a systematic review on the anxiolytic effects of aromatherapy in people with anxiety symptoms, no participants reported experiencing any adverse effects., The use of lavender also appears to help sleep without the adverse effects of commonly used drugs. The anxiolytic effects of the oil might reduce unhealthy behaviors that students engage in, e.g. alcohol and drug use\u002Foveruse, to reduce stress and relax, and positively affect sleep. In a 2015-2016 study of Pace nursing students, the results showed improvement in sleep and test anxiety, although the sample was small.",[28,370,371,372],"Stress","Anxiety","Aromatherapy",[374,375,376,321,377,378],"aromatherapy","nursingstudent","testanxiety","GPA","stress","2024-09-16",{"date":381,"type":52},"2024-09-19",{"date":383,"type":21},"2024-10-01",{"date":385,"type":21},"2025-12-31",{"name":387,"class":59},"Pace University",{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":397,"phases":4,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":60},"100560855","mechanisms-of-action-for-the-enterra-medical-gastric-electrical-stimulator-100560855","NCT06582576","Mechanisms of Action for the Enterra Medical Gastric Electrical Stimulator","Investigation of the Putative Mechanisms Underlying the Symptom-lowering Effect of the Enterra Medical Gastric Electrical Stimulator for Gastroparesis Treatment","Inclusion Criteria:\n\n* Age 18 and above\n* Able to read and understand Danish\n* Have an implanted gastric electrical stimulator for treating gastroparesis\n* Answering 0 or 1 (non-responders) or 3 or 4 (responders) on the Likert scale describing the symptom improvement gained by gastric electrical stimulation.\n* Personally signed and dated the informed consent documents (\"Informeret samtykke\") indicating that the patient has been informed of all pertinent aspects of the trial\n* Are willing and able to comply with the scheduled visit and trial procedures\n\nExclusion Criteria:\n\n* Previous surgery on the vagus nerve, including cervical vagotomy\n* Prior thoracic, abdominal or brain surgeries that, in the opinion of the investigator, could limit data collection or interpretation.\n* Previous diagnosis or history of orthostatic intolerance, e.g. POTS, neurocardiogenic syncope, orthostatic hypotension or autonomic dysfunction.\n* Patients with an implanted cardiac device (e.g. pacemaker, CRT, etc.) or vagal nerve stimulator (VNS).\n* History of neurological disease that, in the opinion of the investigator, could limit data collection or interpretation.\n* Participants with any clinical abnormalities that, in the opinion of the investigator, may increase the risk associated with trial participation or may interfere with the interpretation of the trial results",{"count":396,"type":21},30,"OBSERVATIONAL","Background: Gastric electrical stimulation applied by a surgically implanted device effectively alleviates upper gastrointestinal symptoms in the majority of individuals with medically refractory gastroparesis. Despite its efficacy, the mechanisms of action have been minimally explored in previous studies, and it is unknown why some individuals experience limited symptom-lowering effects.\n\nAim: The investigators aim to investigate two of the potential mechanisms of action leading to symptom-reducing effects of gastric electrical stimulation: 1) possible central effects in the brainstem and brain by enhanced parasympathetic vagal activity, and 2) peripheral effects in the stomach by improved gastric accommodation.\n\nMethods: Up to thirty individuals with drug-refractory gastroparesis having an implanted gastric electrical stimulator will be enrolled in this cross-sectional and observational study. Of these, 15 will be responders (substantial symptomatic improvement) and 15 non-responders (minor symptomatic improvement). Electroencephalography (EEG) will evaluate the stimulation-induced activity in the brain and brainstem to assess whether the gastric stimulation generates evoked potentials. Electrocardiography (ECG) will investigate stimulation-induced changes in the autonomic regulation of the heart. Gastric ultrasound will investigate the effect of stimulation on stomach accommodation, contractions, and wall tension. These central and peripheral measures will be assessed during one study day before and after activating the gastric electrical stimulator, following an increase in stimulation intensity and post-meal consumption. Furthermore, results will be compared between responders and non-responders.\n\nPerspectives: Adjusting the parameters of gastric electrical stimulation based on objective markers in the brain, heart, or stomach, rather than relying on symptom fluctuations, may enhance the effectiveness of symptom improvement. In the future, these objective markers may aid in differentiating between responders and non-responders, which may lead to optimised selection criteria for surgery.",[400,29,28],"Gastroparesis","2024-09-03",{"date":381,"type":52},{"date":404,"type":52},"2024-09-02",{"date":406,"type":21},"2025-10-01",{"name":408,"class":59},"University of Aarhus",{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":232,"sex":17,"minAge":18,"maxAge":417,"enrollmentInfo":418,"targetDuration":420,"studyType":397,"phases":4,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":60},"100498046","safe-brain-initiative-operationalizing-precision-anaesthesia-100498046","NCT05765162","Safe Brain Initiative, Operationalizing Precision Anaesthesia","Safe Brain Initiative - Dedicated to Advancing Anaesthesia and Perioperative Personalised Care Towards Precision Anaesthesia Care. A Continuous Quality Improvement Initiative.","SBI","Inclusion Criteria:\n\n• All patients from age ≥18\n\nExclusion Criteria:\n\n• All patients from age \\\u003C18","100 Years",{"count":419,"type":21},15000,"5 Years","Perioperatively, patients experience an unnecessarily high level of side effects associated with their treatment. These side effects include nausea, severe pain, anxiety, and stress. Moreover, many patients develop postoperative delirium (POD) and neurocognitive dysfunctions, often resulting in long-term cognitive impairment, decreased quality of life, and increased mortality. However, physicians, nurses and their institutions do not receive structured feedback regarding these aspects of each patient's well-being. They may therefore be unable to engage in the essential cause-and-effect learning necessary to evaluate and consecutively reduce such side effects.\n\nEffective guidelines conform prevention is the proven key to shielding our patients from adverse Outcomes. The Safe Brain Initiative's high-quality routine data-for-action is a sword and accelerator for moving towards patient-centred, precision care. Thus, establishing a foundation for value-based and patient-centred healthcare development.\n\nHowever, a turnkey real-world solution is challenging to develop and implement and requires substantial resources. As a result, such solutions are usually beyond the scope of a single institution. The SBI platform provides high-quality, real-world data to bridge this gap. It allows monitoring and in-depth analysis of cause and effect in the day-to-day routine of individuals, departments, and institutions.\n\nThe SBI's approach is continuously improved and updated. An organization called the SBI Global Society oversees the quality and precision of science through experts in the field. At SBI Hospitals and Flagship centres, Masterclasses are conducted and can be attended alongside clinical immersions.\n\nSBI Solutions manages, develops, and provides technical and service support for the Safe Brain Initiative. Its service guarantees the professional and GDPR conform management of data handling and storage as well as the user-friendly functionality of the SBI-Dashboard solutions.",[423,424,345,28,29,425,426,371,370,427,428,429,430,431,432,433,434],"Neurocognitive Disorders","Post Operative Delirium","Wellbeing","Shivering","Agitation,Psychomotor","Sedation Complication","Thirst","Satisfaction, Patient","Temperature Change, Body","Fasting","Sore-throat","Hearing and Vision Loss","2024-06-05",{"date":437,"type":52},"2024-06-07",{"date":439,"type":52},"2021-12-01",{"date":441,"type":21},"2026-01-01",{"name":443,"class":59},"University of Southern Denmark"]